Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

Rachel Woodford, Yanni Loh, Joanna Lee, Wendy Cooper, Ian Marschner, Craig R. Lewis, Michael Millward, Sally Lord, Richard J. Gralla, James C.H. Yang, Tony Mok, Chee K. Lee

Research output: Contribution to journalReview article

Abstract

We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

Original languageEnglish (US)
Pages (from-to)2371-2383
Number of pages13
JournalFuture Oncology
Volume15
Issue number20
DOIs
StatePublished - Jul 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Randomized Controlled Trials
Patient Selection
Disease-Free Survival
Meta-Analysis
Therapeutics

Keywords

  • chemoimmunotherapy
  • meta-analysis
  • non-small-cell lung cancer
  • PD-L1 expression
  • progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Woodford, R., Loh, Y., Lee, J., Cooper, W., Marschner, I., Lewis, C. R., ... Lee, C. K. (2019). Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncology, 15(20), 2371-2383. https://doi.org/10.2217/fon-2019-0105

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. / Woodford, Rachel; Loh, Yanni; Lee, Joanna; Cooper, Wendy; Marschner, Ian; Lewis, Craig R.; Millward, Michael; Lord, Sally; Gralla, Richard J.; Yang, James C.H.; Mok, Tony; Lee, Chee K.

In: Future Oncology, Vol. 15, No. 20, 01.07.2019, p. 2371-2383.

Research output: Contribution to journalReview article

Woodford, R, Loh, Y, Lee, J, Cooper, W, Marschner, I, Lewis, CR, Millward, M, Lord, S, Gralla, RJ, Yang, JCH, Mok, T & Lee, CK 2019, 'Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer', Future Oncology, vol. 15, no. 20, pp. 2371-2383. https://doi.org/10.2217/fon-2019-0105
Woodford, Rachel ; Loh, Yanni ; Lee, Joanna ; Cooper, Wendy ; Marschner, Ian ; Lewis, Craig R. ; Millward, Michael ; Lord, Sally ; Gralla, Richard J. ; Yang, James C.H. ; Mok, Tony ; Lee, Chee K. / Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. In: Future Oncology. 2019 ; Vol. 15, No. 20. pp. 2371-2383.
@article{4bebf76ceb2245d8aca27bc3be8b0a54,
title = "Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer",
abstract = "We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95{\%} CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95{\%} CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95{\%} CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95{\%} CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.",
keywords = "chemoimmunotherapy, meta-analysis, non-small-cell lung cancer, PD-L1 expression, progression-free survival",
author = "Rachel Woodford and Yanni Loh and Joanna Lee and Wendy Cooper and Ian Marschner and Lewis, {Craig R.} and Michael Millward and Sally Lord and Gralla, {Richard J.} and Yang, {James C.H.} and Tony Mok and Lee, {Chee K.}",
year = "2019",
month = "7",
day = "1",
doi = "10.2217/fon-2019-0105",
language = "English (US)",
volume = "15",
pages = "2371--2383",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "20",

}

TY - JOUR

T1 - Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

AU - Woodford, Rachel

AU - Loh, Yanni

AU - Lee, Joanna

AU - Cooper, Wendy

AU - Marschner, Ian

AU - Lewis, Craig R.

AU - Millward, Michael

AU - Lord, Sally

AU - Gralla, Richard J.

AU - Yang, James C.H.

AU - Mok, Tony

AU - Lee, Chee K.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

AB - We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

KW - chemoimmunotherapy

KW - meta-analysis

KW - non-small-cell lung cancer

KW - PD-L1 expression

KW - progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=85070102898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070102898&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0105

DO - 10.2217/fon-2019-0105

M3 - Review article

AN - SCOPUS:85070102898

VL - 15

SP - 2371

EP - 2383

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 20

ER -